Evaluation of new antibiotic cocktails against contaminating bacteria found in allograft tissues

Agnese Serafini · Erika Riello · Diletta Trojan · Elisa Cogliati · Giorgio Palù · Riccardo Manganelli · Adolfo Paolini

Received: 13 April 2016 / Accepted: 1 September 2016 / Published online: 7 September 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract
Contamination of retrieved tissues is a major problem for allograft safety. Consequently, tissue banks have implemented decontamination protocols to eliminate microorganisms from tissues. Despite the widespread adoption of these protocols, few comprehensive studies validating such methods have been published. In this manuscript we compare the bactericidal activity of different antibiotic cocktails at different temperatures against a panel of bacterial species frequently isolated in allograft tissues collected at the Treviso Tissue Bank Foundation, a reference organization of the Veneto Region in Italy that was instituted to select, recover, process, store and distribute human tissues. We were able to identify at least two different formulations capable of killing most of the bacteria during prolonged incubation at 4 °C.

Keywords Antibiotic cocktail · Tissue banking · Bioburden · Microbiology · Decontamination protocol

Introduction
Microbiological contamination of retrieved tissues is a very important topic and a critical aspect of allograft safety, especially when dealing with multi-tissue donors. Tissues retrieved from cadavers and living donors are frequently contaminated as a consequence of the retrieval and handling process, as well as the donor’s inherent bio-burden. Contaminated tissues may represent a potential hazard to recipients, and may only be implanted in the new host when proven to be efficiently decontaminated (Gottesdiener 1989; Eastlund 2006). The spectrum and frequency of bacterial contamination in tissues is very heterogeneous, mainly depending on tissue and donor type. Heart valves are usually more contaminated than musculoskeletal tissues (Ireland and Spelman 2005). In addition, it is well known that commensal bacteria (e.g. Staphylococci) and enteric bacteria are the most prevalent isolated organisms (van Kats et al. 2010). Despite measures to minimize contamination, such as the reduction of cadaver time (the time elapsed between death and start of retrieval) and the number of persons attending the retrieval, there is always a risk.
of bacterial contamination. Consequently, decontamination is a critical aspect, and tissue banks worldwide have established a wide variety of protocols to eliminate bacteria and fungi from isolated tissues (Steffen et al. 2015; Jashari et al. 2007; Heng et al. 2013). The common decontamination procedure usually includes a treatment with an antibiotic cocktail at 4 °C (Germain et al. 2010); however, the decontamination methods used in 17 European cardiovascular tissue banks were recently found to have large methodological differences (composition of cocktails, time and temperature of treatment), suggesting the need to validate and standardize the procedures (De By et al. 2012).

The aim of this study is to identify a new cocktail more efficient at low temperatures than the one currently used at Treviso Tissue Bank Foundation (FBTV), a reference organization of the Veneto Region in Italy instituted for the purpose of selecting, recovering, processing, storing and distributing musculoskeletal and cardiovascular tissues and amniotic membranes.

Recently, Pitt et al. (2014) compared the activity of different antibiotic cocktails used in tissue banks in the United Kingdom at different temperatures against bacteria commonly isolated from contaminated tissues. As expected, the efficacy of the cocktails increased with temperature; however, cocktails containing ciprofloxacin, gentamicin and imipenem were those whose efficacy was less affected by temperature with a good efficacy also at 4 °C, the temperature of choice to decontaminate allografts. Since the cocktail currently in use at FBTV does not include any of these drugs, we hypothesised that we could increase decontamination efficacy using a new cocktail including them. Based on this hypothesis, we formulated and tested new antibiotic combinations including ciprofloxacin, gentamicin and imipenem, against a panel of bacterial species frequently isolated in tissues collected by FBTV, comparing their activity with that of the cocktail currently in use.

Methods

Identification of bacteria contaminating allograft tissues

Following collection from living or cadaveric donors, tissues were decontaminated twice: initially upon retrieval and subsequently after processing. Each decontamination step entailed incubation for 24–48 h at 4 °C in RPMI containing ceftazidime 240 μg/ml (Fresenius-Kabi), lincomycin 120 μg/ml, polymyxin B 100 μg/ml (Biochrom) and vancomycin 50 μg/ml (Hospira). Samples for microbiological analyses were collected upon retrieval and after each decontamination step. Samples were cultured using BD BACTEC Fluorescent Test Technology (BM BACTECTM plus aerobic/F and anaerobic/F culture vials); Soybean-casein digest broth was used in a qualitative procedure for aerobic/anaerobic culture and recovery of bacteria and yeast. If positive, bacteria were isolated and identified using standard procedures.

Bacterial strains, standard media and growth condition

Table 1 shows the 34 strains belonging to 28 bacterial species used in this study and their source. The strains were routinely grown at 37 °C in a controlled atmosphere (Tab. S1) in Blood agar, Chocolate agar (Haemophylus and Granulicatella genus) or MacConkey (Proteus, in order to avoid swarming motility). Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) estimations were performed in standard media used in clinical practice: Mueller–Hinton II Broth Cation adjusted (Thermo Fisher) supplemented with 2–5 % horse lysed blood when needed (Streptococcus, Corynebacterium and Gemella genera), Brucella Broth (Thermo Fisher) supplemented with 10 mg/l vitamin K, 5 mg/l hemin and 5 % horse lysed blood (anaerobes and Granulicatella genera). Antibiotic stock solutions for polymyxin B (Biochrom), meropenem (Fresenius Kabi Italia), ceftazidime (Teva) and vancomycin (Normon) were prepared in water and stored at −80 °C in 30–40 μl aliquots. For the other drugs, we used commercially available ready-to-use injectable solutions: ciprofloxacin (Ciproxin 2 mg/ml, Fresenius Kabi Italia), gentamicin sulphate (40 mg/ml, Fisiopharma) and lincomycin (300 mg/ml Pfizer).

Antimicrobial susceptibility

A 0.5 McFarland bacterial suspension (10^7–10^8 cells/ml) was diluted 1:100 in 11 ml of Mueller–Hinton II broth and aliquoted in a transparent 96-well plate (100 μl/well = 10^4–10^5 cells/well). In the first well,
100 µl of 2× antibiotic solution were added and then 1:2 scalar dilutions were performed. The final antibiotic concentration/well for each antibiotic is indicated in Table S2. As a consequence of the 1:2 dilutions, the final amount of cells was reduced to $10^3$–$10^4$ cells/well. The 96-well plates were incubated at 37 °C until the appearance of a “pellet” at the bottom or cloudiness in the control well (without antibiotic). The minimum concentration able to inhibit growth (no pellet or cloudiness) was recorded as the MIC.

Samples from the first three wells with no growth were spread on solid medium plates and incubated at 37 °C for 24–96 h (depending on the genus) to evaluate the MBC.

**Antibiotic cocktail formulations**

The FBTV foundation currently uses a combination of 4 antibiotics, indicated in Table 2 as cocktail Z. Recently, Pitt et al. (2014) on behalf of National

---

**Table 1** List of the strains used in this work

| Bacterial species                          | Strain name          | Source |
|-------------------------------------------|----------------------|--------|
| Achromobacter xilosoxidans denitrificans  | CIP 77.15T           | PC     |
| Acinetobacter baumannii                   | AS1                  | MVP    |
| Aerococcus viridans                       | AS2                  | MVP    |
| Aeromonas hydrophila                      | AS3                  | MVP    |
| Bacteroides fragilis                      | AS4                  | MVP    |
| Corynebacterium striatum                  | AS5                  | MVP    |
| Enterococcus faecalis                     | ATCC29212            | ATCC   |
| Enterococcus faecalis                     | ATCC51299            | ATCC   |
| Escherichia coli                          | ATCC25922            | ATCC   |
| Gemella morbillorum                       | CIP 81.10T           | PC     |
| Granulicatella adiacens                   | AS6                  | MVP    |
| Haemophilus parainfluenzae                | AS7                  | MVP    |
| Klebsiella pneumoniae                     | ATCC700603           | ATCC   |
| Klebsiella pneumoniae                     | ATCC1706             | ATCC   |
| Kocuria kristinae                         | CIP 81.69T           | PC     |
| Lactobacillus salivarius                  | AS7                  | MVP    |
| Leuconostoc mesenteroides mesenteroides   | CIP 102388           | PC     |
| Micrococcus luteus                        | AS8                  | MVP    |
| Moraxella osloensis                       | CIP 100025           | PC     |
| Peptostreptococcus anaerobius             | CIP 104411T          | PC     |
| Propionibacterium acnes                   | AS9                  | MVP    |
| Proteus mirabilis                         | AS10                 | MVP    |
| Proteus mirabilis                         | AS11                 | MVP    |
| Staphylococcus aureus                     | AS12 (MRSA)          | MVP    |
| Staphylococcus aureus                     | ATCC2913 (MSSA)      | ATTC   |
| Staphylococcus epidermidis                | AS13                 | MVP    |
| Staphylococcus epidermidis                | AS14                 | MVP    |
| Staphylococcus hominis                    | AS15                 | MVP    |
| Staphylococcus hominis                    | AS16                 | MVP    |
| Staphylococcus hominis                    | AS17                 | MVP    |
| Sphingomonas paucimobilis                 | CIP 100752T          | PC     |
| Streptococcus agalactiae                  | AS18                 | MVP    |
| Streptococcus mitis                       | AS19                 | MVP    |
| Streptococcus salivarius                  | AS20                 | MVP    |

PC: Pasteur collection; MVP: microbiology and virology operating unit, Padua hospital agency; ATCC: collection.
Health Service Blood and Transplant (NHSBT) compared bactericidal activity of several antibacterial and anti-fungal drugs combinations in bacterial and fungal strains commonly contaminating allograft tissues (some of which expressed significant levels of antibiotic resistance) at 4, 22 and at 37 °C. In this study, the cocktails with the highest efficacy at 4 °C were those ones containing gentamicin, vancomycin and imipenem or ciprofloxacin. On the basis of their data, we formulated 4 new cocktails (named A, B, C and D) containing different combinations of the antibiotics used by Pitt et al., but excluding the anti-fungal drugs (Table 2). Moreover, we replaced imipenem with meropenem due to its better availability and lower cost. We performed an initial preliminary screening test to evaluate the bactericidal activity of the test cocktails on 4 of the 34 selected bacterial strains (two Gram-positive and two Gram-negative strains with different MBC levels: *Escherichia coli*, *Proteus mirabilis* AS10, *Staphylococcus aureus* MSSA and *Staphylococcus hominis* AS15). The assay was performed by incubating bacteria in the cocktail for 24 or 48 h at 4 °C. Based on this preliminary experiment, we observed that cocktails A and B had lower activity than the others against *Staphylococcus* strains, and were therefore excluded from further analysis.

### Cocktail evaluation

A 0.5 McFarland bacterial suspension (10^7–10^8 cells/ml) was diluted 1:100 (10^5–10^6 cells/ml) in 2.5 ml of BASE medium (Alchimia) to which 0.5 % of fetal calf serum and the different antibiotic cocktails were added. Samples were incubated at 22 or 4 °C without shaking. The number of CFU/ml was determined at different time points after adding the cocktail (T0, T6 h for samples incubated at 22 °C and T0, T24 h and T48 h for samples incubated at 4 °C). Viable counts (CFU/ml) were determined by plating 1:10 scalar dilutions of the bacterial suspension on solid media and counting the resulting colonies after incubation in the proper conditions. To avoid antibiotic carry-over, bacteria were pelleted at 10,000g for 5’ at 4 °C and suspended in the same volume of fresh medium before dilution. The bactericidal activity was calculated as:

\[\frac{\text{(CFU/ml after treatment)}}{\text{(CFU/ml before treatment)}} \times 100\]

### Results

Bacterial species isolated from allograft tissues after decontamination

To select a panel of bacterial strains representing those currently contaminating tissues, we conducted a survey in 2012 and 2013 to isolate and identify all contaminating bacteria found in allografts at FBTV following the protocol actually used at FBTV reported in the Methods section. We singled out 102 bacterial species belonging to 47 genera (Tab. S3). Non-compliers species, according to FBTV policy (*Clostridium* spp., *Fungi/yeasts*, *Mycobacterium* spp., *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Serratia marcescens* and *Meningococcus* spp.), were excluded from the list. Species isolated in at least three different tissues (27 species belonging to 23 different genera), were selected for this study. For frequently detected species we decided to analyse more than one strain, making a total of 34 strains (Table 1).

### Assessment of antibiotic MBCs

To obtain a theoretical indication of the efficacy of the cocktails, we evaluated the MIC and MBC of each antibiotic for all strains (Table 3). Comparing the MBCs of the various strains, we made the following overall observations: (a) meropenem is the antibiotic with the greatest bactericidal effect, showing an MBC ≤1 µg/ml on 65 % of the strains, followed by ciprofloxacin with an MBC ≤2 µg/ml on 62 % of the strains; (b) meropenem and ciprofloxacin have a

### Table 2 Antibiotic cocktails used in this study

| Antibiotic | Antibiotic cocktail (µg/ml) |
|------------|-----------------------------|
|            | Z | A | B | C | D |
| Ciprofloxacin | – | 200 | 200 | – | 200 |
| Ceftazidime  | 240 | – | – | – | – |
| Gentamicin   | – | 200 | – | 200 | 200 |
| Ciprofloxacin | 200 | – | 200 | 200 | 200 |
| Polymyxin B  | 100 | – | – | – |
| Vancomycin   | 50 | 100 | 100 | 100 | 100 |
|                          | Vancomycin | Meropenem | Ceftazidime | Ciprofloxacin | Polymyxin B | Lincomycin | Gentamicin |
|--------------------------|------------|-----------|-------------|---------------|-------------|------------|------------|
|                          | MIC        | MBC       | MIC         | MBC           | MIC         | MBC        | MIC        | MBC        |
| *Achromobacter xilosidan*| >32        | >32       | 0.5         | 0.5           |             |            | >128       | >128       |
| *Acinetobacter baumannii*| >32        | >32       | ≤0.25       | ≤0.25         | 8           | 8          | >128       | >128       |
| *Aerococcus viridans*    | 0.125      | 0.5       | 0.25        | 0.25          | 1           | >4         | 2          | 2          |
| *Aeromonas hydrophila*   | 32         | 32        | ≤0.25       | ≤0.25         | ≤0.25       | ≤0.25      | 0.5        | 0.5        |
| *Bacteroides fragilis*   | 8          | 16        | ≤0.25       | ≤0.25         | >128        | >128       | 0.5        | 0.5        |
| *Corynebacterium striatum*| 0.25       | 0.25      | 0.5         | 1             | 128         | >128       | 32         | 32         |
| *Enterococcus faecalis ATCC29212* | 8         | >32       | 16          | 128           | >128        | 0.5        | 8          | ≥0.25       |
| *Escherichia coli*       | >32        | >32       | ≤0.25       | ≤0.25         | ≤0.25       | ≤0.25      | 0.5        | 0.5        |
| *Gemella morbillorum*    | 0.5        | >2        | ≤0.25       | ≤0.25         | 0.25        | 0.5        | >0.25      | ≤0.25      |
| *Granulicatella adiacens*| 1          | 1         | ≤0.25       | ≤0.25         | 1           | >4         | 0.5        | >0.25      |
| *Haemophilus parainfluenzae* | >32       | >32       | ≤0.25       | ≤0.25         | ≤0.25       | ≤0.25      | 0.5        | 0.5        |
| *Klebsiella pneumoniae ATCC700603* | >32     | >32       | ≤0.25       | ≤0.25         | 32          | 32         | 0.25       | >0.25     |
| *Klebsiella pneumoniae ATCC1706* | >32     | >32       | 2           | 16            | 32          | 32         | 4          | >0.25     |
| *Kocuria kristinae*      | 1          | 2         | 1           | 1             | 64          | 128        | 1          | 2          |
| *Lactococillus salivarium* | 32        | >32       | 2           | 4             | 32          | 32         | 2          | 4          |
| *Leuconostoc mesenteroides* | >32       | >32       | 32          | 32            | >128        | >128       | 2          | 4          |
| *Micrococcus luteus*     | 1          | 1         | ≤0.25       | ≤0.25         | 32          | 32         | 1          | 2          |
| *Moraxella osloensis*    | 16         | 16        | ≤0.25       | ≤0.25         | 4           | 4          | ≤0.06      | ≤0.06      |
| *Peptostreptococcus*     | 0.25       | 0.25      | ≤0.25       | ≤0.25         | 1           | 1          | 0.5        | 1          |
| *Propionibacterium acnes* | 0.5        | 0.5       | ≤0.25       | ≤0.25         | 1           | 4          | 0.5        | 0.5        |
| *Proteus mirabilis AS10* | >32        | >32       | ≤0.25       | ≤0.25         | 8           | 8          | 1          | 2          |
| *Proteus mirabilis AS11* | >32        | >32       | ≤0.25       | ≤0.25         | 2           | ≤0.25      | >0.25      | >0.25      |
| *Sphingomonas paucimobilis* | 8         | 32        | ≤0.25       | ≤0.25         | 4           | 8          | 1          | 2          |
| *Staphylococcus aureus MRSA* | 1         | 1         | 2           | 8             | 128         | 128        | >32        | >32        |
| *Staphylococcus aureus MSSA* | 1         | 1         | ≤0.25       | 2             | 4           | 8          | 125        | 0.5        |
| *Staphylococcus epidermidis AS13* | 2         | 4         | 16          | >16           | 64          | 128        | 32         | >32        |
| *Staphylococcus epidermidis AS14* | 2         | 2         | ≤0.25       | 1             | 8           | 8          | ≤0.06      | 1          |
| *Staphylococcus hominis AS15* | 1         | >4        | 2           | 4             | 64          | 64         | >32        | >32        |
| *Staphylococcus hominis AS16* | 0.5       | 2         | 1           | 4             | 32          | 128        | >32        | >32        |
broad spectrum of action; (c) polymyxin B, ceftazidime and lincomycin showed the lowest bactericidal effect on most of the strains analysed, killing just 35, 53 and 39 % of the strains respectively, at a concentration of ≤8 μg/ml; (d) gentamicin resulted to be the best antibiotic or one the best for particularly low susceptible strains as *Klebsiella pneumoniae* ATCC1706, *Leuconostoc mesenteroides* and *Enterococcus faecalis* ATCC29212.

Efficacy of antibiotic cocktails at 4 °C

The efficacy of cocktails C and D at 4 °C was compared with that of the cocktail currently used at FBTV (cocktail Z). Figure 1 reports the bactericidal activity of cocktails Z, C and D for each strain, and clearly shows that the bactericidal activity of cocktails C and D was higher than that of cocktail Z on several bacterial strains, in particular against those belonging to *Streptococcus* and *Staphylococcus* genera. As expected, the activity increased with the extension of the treatment to 48 h (Figs. 1, 2). In particular, 21 out of 34 (61 %) and 23 out of 34 (67 %) total strains showed a kill rate higher than 95 % when incubated with cocktail C or D, respectively, compared to only 15 out of 34 (44 %) total strains for cocktail Z (Fig. 3a).

Efficacy of antibiotic cocktails at 22 °C

To evaluate the possibility of treating tissues at higher temperatures but for shorter periods, we tested the efficacy of these cocktails at 22 °C for 6 h. As expected, under such conditions the bactericidal activity of the cocktails was higher than at 4 °C, exceeding 95 % in most strains (Fig. 4). Again, cocktails C and D showed greater bactericidal activity: 28 out of 34 (82 %) and 29 out of 34 (85 %) total strains showed a kill rate higher than 95 % when incubated with cocktail C or D, respectively, compared to only 21 out of 34 (62 %) for cocktail Z (Fig. 3b).

**Discussion**

Tissue decontamination is a challenge for tissue banks. However, the standardization and validation of specific decontamination procedures and antibiotic
Fig. 1 Bactericidal activity of antibiotic cocktails at 4 °C. Data shown as % kill; NG no growth

Fig. 2 Effect of incubation time on bactericidal activity at 4 °C. The graph shows the number of strains killed at a rate higher than 95% after treatment for 24 and 48 h with different antibiotic cocktails (Z, C and D).

cocktails have rarely been pursued, consequently a wide range of antibiotic formulations, temperatures and exposure times are currently adopted for this purpose (Heng et al. 2013; De By et al. 2012; Germain et al. 2010).

Taking the assessments reported by Pitt et al. (2014), on the efficacy of different antibiotic cocktails at 4 and 22 °C against a wide panel of bacterial strains, we designed 4 different antibiotic cocktails. After a preliminary screening we focused on two of them which were tested against a panel of bacterial species commonly isolated from allograft tissues and compared them to the antibiotic cocktail currently in use in our facility at FBTV (cocktail Z). We did not include any anti-mycotic drugs, since in our procedure the presence of fungi in the pre-decontamination analysis is an exclusion criterion for tissue. For the same reason our bacterial panels did not include *Streptococcus pneumoniae, Streptococcus pyogenes, Serratia marcescens, Meningococcus or Pseudomonas aeruginosa* strains or strains belonging to the genus *Clostridium* or *Mycobacterium*.
The efficacy of the cocktails was tested both at 4 °C for 24 or 48 h and at 22 °C for 6 h. To prevent drug carry-over interfering with the results, the bacteria were rinsed in a drug-free medium before viability counts. Two of the new cocktails (C and D) killed a broad spectrum of bacteria even at 4 °C and were clearly more effective than cocktail Z. Specifically, after incubation for 48 h at 4 °C, 61 and 67 % of the strains showed a kill rate higher than 95 % when incubated with cocktail C or D, respectively, compared to 44 % of the strains reaching the same kill rate when incubated with cocktail Z. This effect was probably due to the broader spectrum of action of the antibiotics contained in the new cocktails compared to cocktail Z (Table 2). Cocktails C and D, both contained vancomycin and gentamicin, plus meropenem (cocktail C) or ciprofloxacin (cocktail D). The superiority of cocktails C and D over cocktail Z mainly lies in their increased bactericidal activity against *Streptococcus* and *Staphylococcus* strains (Fig. 1), which are the most commonly detected genera in allografts. In particular, cocktail D showed a kill rate higher than >90 % activity against all tested strains of *Streptococcus* and *Staphylococcus*. 

![Fig. 3 Effect of temperature on bactericidal activity. a Number of strains and different kill rates at 4 °C for 48 h. b Number of strains and different kill rates at 22 °C for 6 h](image-url)
Treatment at a higher temperature (such as room temperature, 22 °C) for shorter times would increase decontamination efficacy (in particular allowing higher depletion of more resistant species including Enterococcus faecalis) and reduce processing times, however this procedure might not be applicable to all tissues due to their shorter survival at this temperature. It would be interesting in the future to measure tissue vitality at this temperature by performing specific tests, and to assess the efficacy of short decontamination procedures using shorter incubation times.

It is important to point out that susceptibility towards antibiotics varies within species, so the panel of clinical and reference isolates used in this work cannot cover all of the possible susceptibility spectra of bacterial contaminants found in the field. One drawback of our work was that our killing experiments were performed in liquid medium, in different conditions compared to those usually experienced by the bacteria during allograft decontamination. To alleviate this drawback, the medium was added with 0.5 % foetal calf serum to increase the concentration of proteins, which are obviously highly represented in tissues and can bind with antibiotics.

With regard to the above mentioned issue, we will shortly be analysing the microbiological results after one year with the new cocktail to verify its efficacy in allograft decontamination compared to cocktail Z.

**Fig. 4** Bactericidal activity of antibiotic cocktails at 22 °C. Data shown as % kill; NG no growth

|                        | Z       | C       | D       |
|------------------------|---------|---------|---------|
| *Achromobacter xilosoxidans* | NG      | 99.48   | 98.83   |
| *Acinetobacter baumannii* | NG      | NG      | NG      |
| *Aerococcus viridans*   | 94.81   | 99.99   | 99.93   |
| *Aeromonas hydrophyla*  | NG      | NG      | NG      |
| *Bacteroides*           | 81.125  | 82.06   | 97.51   |
| *Corynebacterium striatum* | 99.92   | 99.92   | 99.98   |
| *Enterococcus faecalis ATCC29212* | 74.95   | 99.61   | 69.01   |
| *Enterococcus faecalis ATCC51299* | 44.45   | 86.32   | 62.91   |
| *Escherichia coli*      | NG      | NG      | NG      |
| *Gemella morbillorum*   | 99.92   | 99.91   | 99.83   |
| *Granulicatella adiacens* | 85      | 99.36   | 99.27   |
| *Haemophilus parainfluenzae* | NG      | 99.99   | NG      |
| *Klebsiella pneumoniae ATCC700603* | NG      | 99.92   | 99.55   |
| *Klebsiellae pmenonuniae ATCC1706* | NG      | NG      | 99.99   |
| *Kocuria kristinae*     | 97.15   | 99.98   | 99.98   |
| *Lactobacillus salivarius* | 83.35   | 99.99   | 99.98   |
| *Leuconostoc mesenteroides* | 59.23   | 99.98   | 99.99   |
| *Micrococcus luteus*    | 99.98   | 98.12   | 97.5    |
| *Moraxella osloensis*   | 99.83   | NG      | NG      |
| *Peptostreptococcus anaerobius* | NG      | NG      | NG      |
| *Propionibacterium acnes* | 97.51   | 77.92   | 77.42   |
| *Proteus mirabilis AS10* | 99.84   | 99.81   | 65.83   |
| *Proteus mirabilis AS11* | 97.41   | 99.98   | 99.99   |
| *Sphingomonas paucimobilis* | NG      | NG      | NG      |
| *Staphylococcus aureus AS12* (MRSA) | 85      | 99.98   | 99.97   |
| *Staphylococcus aureus ATCC2913* (MSSA) | 94.36   | 99.99   | 99.98   |
| *Staphylococcus epidermidis AS13* | 71.11   | 77.3    | 98.79   |
| *Staphylococcus epidermidis AS14* | 96.66   | NG      | NG      |
| *Staphylococcus hominis AS15* | NG      | 81.34   | 76.83   |
| *Staphylococcus hominis AS16* | NG      | 85.9    | 95.72   |
| *Staphylococcus hominis AS17* | NG      | NG      | NG      |
| *Streptococcus mitis*   | 49.61   | NG      | NG      |
| *Streptococcus agalactiae* | 78.24   | NG      | 99.93   |
| *Streptococcus salivarius* | 85.43   | NG      | 99.99   |
It is also worth noting that our experiments were performed starting with cultures that had a bacterial concentration of $10^5$–$10^6$ cells/ml, a much higher load than that found in allograft tissues, since a drug’s kill rate is usually inversely proportional to the bacterial load (i.e. inoculum effect; Udekwu et al. 2009); the bactericidal activity shown in Figs. 1 and 4 might be underestimated with respect to that obtained during allograft decontamination.

In conclusion, in this work we characterized two antibiotic formulations that displayed several advantages validating our initial hypothesis that a cocktail including gentamicin, ciprofloxacin or meropenem would be more efficient than the one currently in use at FBTV (cocktail Z): (1) both were found to be more potent both at 4 and at 22 °C; (2) both contained three antibiotics instead of four, reducing the cost of decontamination; and (3) both contained antibiotics which are more readily available than lyncomycin and polymyxin B (present in cocktail Z), as they are commonly used in clinical practice. In addition, in Italy polymyxin B is no longer available as an antibiotic for systemic use, but only for topical use due to its toxicity.

Acknowledgments  We thank Lucia Rossi, Ettore De Canale, Alessandro Berto and Nicola Menegotto (Microbiology and Virology Operating Unit of Padua Hospital Agency) for collecting ATCC and clinical isolated strains and all the technical staff for their technical support.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

De By TM, Parker R, Delmo Walter EM, Hetzer R (2012) Cardiovascular tissue banking in Europe. HSR Proc Intensive Care Cardiovasc Anesth 4:251–260

Eastlund T (2006) Bacterial infection transmitted by human tissue allograft transplantation. Cell Tissue Bank 7:147–166

Germain M, Thibault L, Jacques A, Tremblay J, Bourgeois R (2010) Heart valve allograft decontamination with antibiotics: impact of the temperature of incubation on efficacy. Cell Tissue Bank 11:197–204

Gottesdiener KM (1989) Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med 110:1001–1016

Heng WL, Albrecht H, Chiappini P, Lim YP, Manning L (2013) International heart valve bank survey: a review of processing practices and activity outcomes. J Transplant 2013:163150. doi:10.1155/2013/163150

Ireland L, Spelman D (2005) Bacterial contamination of tissue allografts—experiences of the donor tissue bank of Victoria. Cell Tissue Bank 6:181–189

Jashari R, Tabaku M, Van Hoeck B, Cochez C, Callant M, Vanderkelen A (2007) Decontamination of heart valve and arterial allografts in the European Homograft Bank (EHB): comparison of two different antibiotic cocktails in low temperature conditions. Cell Tissue Bank 8:247–255

Pitt TL, Tidey K, Roy A, Ancliff S, Lomas R et al (2014) Activity of four antimicrobial cocktails for tissue allograft decontamination against bacteria and Candida spp. of known susceptibility at different temperatures. Cell Tissue Bank 15:119–125

Steffen V, Marsch G, Burgwitz K, Kuehn C, Teebken OE (2015) Resistance to infection of long-term cryopreserved human aortic valve allografts. J Thorac Cardiovasc Surg. doi:10.1016/j.jtcs.2015.11.029

Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR (2009) Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63:745–757

van Kats JP, van Tricht C, van Dijk A, van der Schans M, van den Bogaerd A et al (2010) Microbiological examination of donated human cardiac tissue in heart valve banking. Eur J Cardiothorac Surg 37:163–169